Reciprocal Incremental Value of 18 F-FDG-PET and Cerebrospinal Fluid Biomarkers in Mild Cognitive Impairment Patients Suspected for Alzheimer’s Disease and Inconclusive First Biomarker
Restricted accessResearch articleFirst published online December 12, 2019
Reciprocal Incremental Value of 18 F-FDG-PET and Cerebrospinal Fluid Biomarkers in Mild Cognitive Impairment Patients Suspected for Alzheimer’s Disease and Inconclusive First Biomarker
In Alzheimer’s disease (AD) diagnosis, both cerebrospinal fluid (CSF) biomarkers and FDG-PET sometimes give inconclusive results.
Objective:
To evaluate the incremental diagnostic value of FDG-PET over CSF biomarkers, and vice versa, in patients with mild cognitive impairment (MCI) and suspected AD, in which the first biomarker resulted inconclusive.
Methods:
A consecutive series of MCI patients was retrospectively selected from two Memory Clinics where, as per clinical routine, either the first biomarker choice is FDG-PET and CSF biomarkers are only used in patients with uninformative FDG-PET, or vice versa. We defined criteria of uncertainty in interpretation of FDG-PET and CSF biomarkers, according to current evidence. The final diagnosis was established according to clinical-neuropsychological follow-up of at least one year (mean 4.4±2.2).
Results:
When CSF was used as second biomarker after FDG-PET, 14 out of 36 (39%) received informative results. Among these 14 patients, 11 (79%) were correctly classified with respect to final diagnosis, thus with a relative incremental value of CSF over FDG-PET of 30.6%. When FDG-PET was used as second biomarker, 26 out of 39 (67%) received informative results. Among these 26 patients, 15 (58%) were correctly classified by FDG-PET with respect to final diagnosis, thus with a relative incremental value over CSF of 38.5%.
Conclusion:
Our real-world data confirm the added values of FDG-PET (or CSF) in a diagnostic pathway where CSF (or FDG-PET) was used as first biomarkers in suspected AD. These findings should be replicated in larger studies with prospective enrolment according to a Phase III design.
PetersenRC, CaraccioloB, BrayneC, GauthierS, JelicV, FratiglioniL (2014) Mild cognitive impairment: A concept in evolution. J Intern Med275, 214–228.
2.
StephanBCM, HunterS, HarrisD, LlewellynDJ, SiervoM, MatthewsFE, BrayneC (2012) The neuropathological profile of mild cognitive impairment (MCI): A systematic review. Mol Psychiatry17, 1056–1076.
3.
AlbertMS, DeKoskyST, DicksonD, DuboisB, FeldmanHH, FoxNC, GamstA, HoltzmanDM, JagustWJ, PetersenRC, SnyderPJ, CarrilloMC, ThiesB, PhelpsCH (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 270–279.
4.
BerkC, PaulG, SabbaghM (2014) Investigational drugs in Alzheimer’s disease: Current progress. Expert Opin Investig Drugs23, 837–846.
5.
FiandacaMS, MapstoneME, CheemaAK, FederoffHJ (2014) The critical need for defining preclinical biomarkers in Alzheimer’s disease. Alzheimers Dement10, S196–S212.
6.
FrisoniGB, BoccardiM, BarkhofF, BlennowK, CappaS, ChiotisK, DémonetJ-F, GaribottoV, GiannakopoulosP, GietlA, HanssonO, HerholzK, JackCR, NobiliF, NordbergA, SnyderHM, Ten KateM, VarroneA, AlbaneseE, BeckerS, BossuytP, CarrilloMC, CeramiC, DuboisB, GalloV, GiacobiniE, GoldG, HurstS, LönneborgA, LovbladK-O, MattssonN, MolinuevoJ-L, MonschAU, MosimannU, PadovaniA, PiccoA, PorteriC, RatibO, Saint-AubertL, ScerriC, ScheltensP, SchottJM, SonniI, TeipelS, VineisP, VisserPJ, YasuiY, WinbladB (2017) Strategic roadmap for an early diagnosis of Alzheimer’s disease based on biomarkers. Lancet Neurol16, 661–676.
7.
SimonsenAH, HerukkaS-K, AndreasenN, BaldeirasI, BjerkeM, BlennowK, EngelborghsS, FrisoniGB, GabryelewiczT, GalluzziS, HandelsR, KrambergerMG, KulczyńskaA, MolinuevoJL, MroczkoB, NordbergA, OliveiraCR, OttoM, RinneJO, RotU, SakaE, SoininenH, StruyfsH, SuardiS, VisserPJ, WinbladB, ZetterbergH, WaldemarG (2017) Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. Alzheimers Dement13, 274–284.
ShafferJL, PetrellaJR, SheldonFC, ChoudhuryKR, CalhounVD, ColemanRE, DoraiswamyPM, Alzheimer’s Disease Neuroimaging Initiative (2013) Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers. Radiology266, 583–591.
10.
PrestiaA, CaroliA, WadeSK, van der FlierWM, OssenkoppeleR, Van BerckelB, BarkhofF, TeunissenCE, WallA, CarterSF, SchöllM, ChooIH, NordbergA, ScheltensP, FrisoniGB (2015) Prediction of AD dementia by biomarkers following the NIA-AA and IWG diagnostic criteria in MCI patients from three European memory clinics. Alzheimers Dement11, 1191–1201.
11.
CaminitiSP, BallariniT, SalaA, CeramiC, PresottoL, SantangeloR, FallancaF, VanoliEG, GianolliL, IannacconeS, MagnaniG, PeraniD, ParnettiL, EusebiP, FrisoniG, NobiliF, PiccoA, ScarpiniE (2018) FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort. Neuroimage Clin18, 167–177.
12.
CureS, AbramsK, BelgerM, dell’agnelloG, HappichM (2014) Systematic literature review and meta-analysis of diagnostic test accuracy in Alzheimer’s disease and other dementia using autopsy as standard of truth. J Alzheimers Dis42, 169–182.
PrestiaA, CaroliA, HerholzK, ReimanE, ChenK, JagustWJ, FrisoniGB, Translational Outpatient Memory Clinic Working Group, Alzheimer’s Disease Neuroimaging Initiative (2013) Diagnostic accuracy of markers for prodromal Alzheimer’s disease in independent clinical series. Alzheimers Dement9, 677–686.
15.
VemuriP, WisteHJ, WeigandSD, ShawLM, TrojanowskiJQ, WeinerMW, KnopmanDS, PetersenRC, JackCR, Alzheimer’s Disease Neuroimaging Initiative (2009) MRI and CSF biomarkers in normal, MCI, and AD subjects: Predicting future clinical change. Neurology73, 294–301.
16.
BouwmanFH, SchoonenboomSNM, van der FlierWM, van ElkEJ, KokA, BarkhofF, BlankensteinMA, ScheltensP (2007) CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment. Neurobiol Aging28, 1070–1074.
17.
ChooIH, NiR, SchöllM, WallA, AlmkvistO, NordbergA (2013) Combination of 18F-FDG PET and cerebrospinal fluid biomarkers as a better predictor of the progression to Alzheimer’s disease in mild cognitive impairment patients. J Alzheimers Dis33, 929–939.
18.
BoccardiM, NicolosiV, FestariC, BianchettiA, CappaS, ChiasseriniD, FaliniA, GuerraU, NobiliF, PadovaniA, SancesarioGM, MorbelliSD, ParnettiL, TiraboschiP, MuscioC, PeraniD, PizziniFB, BeltramelloA, Salvini PorroG, CiaccioM, SchillaciO, TrabucchiM, TagliaviniF, FrisoniGB (2019) Italian inter-societal consensus for the biomarker-based etiological diagnosis in MCI. 5th Congress of the European Academy of Neurology, Oslo June 29-July 2, 2019. Eur J Neurol26(Suppl 1), 16.
19.
NobiliF, ArbizuJ, BouwmanF, DrzezgaA, AgostaF, NestorP, WalkerZ, BoccardiM, EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders (2018) European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain 18 F-fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus. Eur J Neurol25, 1201–1217.
20.
ArbizuJ, FestariC, AltomareD, WalkerZ, BouwmanF, RivoltaJ, OriniS, BarthelH, AgostaF, DrzezgaA, NestorP, BoccardiM, FrisoniGB, NobiliF, EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders (2018) Clinical utility of FDG-PET for the clinical diagnosis in MCI. Eur J Nucl Med Mol Imaging45, 1497–1508.
21.
JohnsonKA, MinoshimaS, BohnenNI, DonohoeKJ, FosterNL, HerscovitchP, KarlawishJH, RoweCC, CarrilloMC, HartleyDM, HedrickS, PappasV, ThiesWH, Alzheimer’s Association, Society of Nuclear Medicine and Molecular Imaging, Amyloid Imaging Taskforce (2013) Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association. Alzheimers Dement9, E1–E16.
22.
LangeC, SuppaP, PietrzykU, MakowskiMR, SpiesL, PetersO, BuchertR, Alzheimer’s Disease Neuroimaging Initiative (2017) Prediction of Alzheimer’s dementia in patients with amnestic mild cognitive impairment in clinical routine: Incremental value of biomarkers of neurodegeneration and brain amyloidosis added stepwise to cognitive status. J Alzheimers Dis61, 373–388.
GorelickPB, ScuteriA, BlackSE, DeCarliC, GreenbergSM, IadecolaC, LaunerLJ, LaurentS, LopezOL, NyenhuisD, PetersenRC, SchneiderJA, TzourioC, ArnettDK, BennettDA, ChuiHC, HigashidaRT, LindquistR, NilssonPM, RomanGC, SellkeFW, SeshadriS, American Heart Association Stroke Council, Council on Epidemiology and Prevention, Council on Cardiovascular Nursing, Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia (2011) Vascular contributions to cognitive impairment and dementia. Stroke42, 2672–2713.
25.
McKhannGM, KnopmanDS, ChertkowH, HymanBT, JackCR, KawasCH, KlunkWE, KoroshetzWJ, ManlyJJ, MayeuxR, MohsRC, MorrisJC, RossorMN, ScheltensP, CarrilloMC, ThiesB, WeintraubS, PhelpsCH (2011) The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 263–269.
LitvanI, AgidY, CalneD, CampbellG, DuboisB, DuvoisinRC, GoetzCG, GolbeLI, GrafmanJ, GrowdonJH, HallettM, JankovicJ, QuinnNP, TolosaE, ZeeDS (1996) Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): Report of the NINDS-SPSP international workshop. Neurology47, 1–9.
32.
RespondekG, KurzC, ArzbergerT, ComptaY, EnglundE, FergusonLW, GelpiE, GieseA, IrwinDJ, MeissnerWG, NilssonC, PantelyatA, RajputA, van SwietenJC, TroakesC, JosephsKA, LangAE, MollenhauerB, MüllerU, WhitwellJL, AntoniniA, BhatiaKP, BordelonY, CorvolJ-C, ColosimoC, DodelR, GrossmanM, KassubekJ, KrismerF, LevinJ, LorenzlS, MorrisH, NestorP, OertelWH, RabinoviciGD, RoweJB, van EimerenT, WenningGK, BoxerA, GolbeLI, LitvanI, StamelouM, HöglingerGU, Movement Disorder Society-Endorsed PSP Study Group (2017) Which ante mortem clinical features predict progressive supranuclear palsy pathology?Mov Disord32, 995–1005.
33.
TeunissenCE, PetzoldA, BennettJL, BervenFS, BrundinL, ComabellaM, FranciottaD, FrederiksenJL, FlemingJO, FurlanR, Hintzen MDRQ, HughesSG, JohnsonMH, KrasulovaE, KuhleJ, MagnoneMC, RajdaC, RejdakK, SchmidtHK, van PeschV, WaubantE, WolfC, GiovannoniG, HemmerB, TumaniH, DeisenhammerF (2009) A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology73, 1914–1922.
34.
VarroneA, AsenbaumS, Vander BorghtT, BooijJ, NobiliF, NågrenK, DarcourtJ, KapucuÖL, TatschK, BartensteinP, Van LaereK, European Association of Nuclear Medicine Neuroimaging Committee (2009) EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2. Eur J Nucl Med Mol Imaging36, 2103–2110.
MorbelliS, BrugnoloA, BossertI, BuschiazzoA, FrisoniGB, GalluzziS, van BerckelBNM, OssenkoppeleR, PerneczkyR, DrzezgaA, DidicM, GuedjE, SambucetiG, BottoniG, ArnaldiD, PiccoA, De CarliF, PaganiM, NobiliF (2015) Visual versus semi-quantitative analysis of 18F-FDG-PET in amnestic MCI: An European Alzheimer’s Disease Consortium (EADC) Project. J Alzheimers Dis44, 815–826.
37.
NestorPJ, CaineD, FryerTD, ClarkeJ, HodgesJR (2003) The topography of metabolic deficits in posterior cortical atrophy (the visual variant of Alzheimer’s disease) with FDG-PET. J Neurol Neurosurg Psychiatry74, 1521–1529.
38.
WoodwardMC, RoweCC, JonesG, VillemagneVL, VarosTA (2015) Differentiating the frontal presentation of Alzheimer’s disease with FDG-PET. J Alzheimers Dis44, 233–242.
39.
GrimmerT, WutzC, AlexopoulosP, DrzezgaA, ForsterS, ForstlH, GoldhardtO, OrtnerM, SorgC, KurzA (2016) Visual versus fully automated analyses of 18F-FDG and amyloid PET for prediction of dementia due to Alzheimer disease in mild cognitive impairment. J Nucl Med57, 204–207.
40.
BouwmanF, OriniS, GandolfoF, AltomareD, FestariC, AgostaF, ArbizuJ, DrzezgaA, NestorP, NobiliF, WalkerZ, MorbelliS, BoccardiM, EANM-EAN Task Force for the Prescription of FDG-PET for Dementing Neurodegenerative Disorders (2018) Diagnostic utility of FDG-PET in the differential diagnosis between different forms of primary progressive aphasia. Eur J Nucl Med Mol Imaging45, 1526–1533.
41.
WalkerZ, GandolfoF, OriniS, GaribottoV, AgostaF, ArbizuJ, BouwmanF, DrzezgaA, NestorP, BoccardiM, AltomareD, FestariC, NobiliF, EANM-EAN Task Force for the recommendation of FDG PET for Dementing Neurodegenerative Disorders (2018) Clinical utility of FDG PET in Parkinson’s disease and atypical parkinsonism associated with dementia. Eur J Nucl Med Mol Imaging45, 1534–1545.
FellgiebelA, ScheurichA, BartensteinP, MüllerMJ (2007) FDG-PET and CSF phospho-tau for prediction of cognitive decline in mild cognitive impairment. Psychiatry Res Neuroimaging155, 167–171.
44.
WestonPSJ, PatersonRW, DicksonJ, BarnesA, BomanjiJB, KayaniI, LunnMP, MummeryCJ, WarrenJD, RossorMN, FoxNC, ZetterbergH, SchottJM (2016) Diagnosing dementia in the clinical setting: Can amyloid PET provide additional value over cerebrospinal fluid?J Alzheimers Dis54, 1297–1302.
WalhovdKB, FjellAM, BrewerJ, McEvoyLK, Fennema-NotestineC, HaglerDJ, JenningsRG, KarowD, DaleAM, Alzheimer’s Disease Neuroimaging Initiative (2010) Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease. Am J Neuroradiol31, 347–354.
47.
FrölichL, PetersO, LewczukP, GruberO, TeipelSJ, GertzHJ, JahnH, JessenF, KurzA, LuckhausC, HüllM, PantelJ, ReischiesFM, SchröderJ, WagnerM, RienhoffO, WolfS, BauerC, SchuchhardtJ, HeuserI, RütherE, HennF, MaierW, WiltfangJ, KornhuberJ (2017) Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer’s dementia. Alzheimers Res Ther9, 84.
48.
JellingerKA, AttemsJ (2010) Prevalence of dementia disorders in the oldest-old: An autopsy study. Acta Neuropathol119, 421–433.
49.
CarotenutoA, ReaR, ColucciL, ZielloAR, MolinoI, CarpiS, TrainiE, AmentaF, FasanaroAM (2012) Late and early onset dementia: What is the role of vascular factors? A retrospective study. J Neurol Sci322, 170–175.
BeachTG, MonsellSE, PhillipsLE, KukullW (2012) Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J Neuropathol Exp Neurol71, 266–273.
52.
MolinuevoJL, BlennowK, DuboisB, EngelborghsS, LewczukP, Perret-LiaudetA, TeunissenCE, ParnettiL (2014) The clinical use of cerebrospinal fluid biomarker testing for Alzheimer’s disease diagnosis: A consensus paper from the Alzheimer’s Biomarkers Standardization Initiative. Alzheimers Dement10, 808–817.
53.
LewczukP, KornhuberJ, ToledoJB, TrojanowskiJQ, Knapik-CzajkaM, PetersO, WiltfangJ, ShawLM, ShawLM, US-ADNI (2015) Validation of the Erlangen Score Algorithm for the prediction of the development of dementia due to Alzheimer’s disease in pre-dementia subjects. J Alzheimers Dis48, 433–441.
54.
AlexopoulosP, WerleL, RoeslerJ, ThierjungN, GleixnerLS, YakushevI, LaskarisN, WagenpfeilS, GourzisP, KurzA, PerneczkyR, Alzheimer’s Disease Neuroimaging Initiative (ADNI) (2016) Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer’s disease. Alzheimers Res Ther8, 51.
55.
RosénC, FarahmandB, SkillbäckT, NäggaK, MattssonN, KilanderL, ReligaD, WimoA, BlennowK, WinbladB, ZetterbergH, EriksdotterM (2015) Benchmarking biomarker-based criteria for Alzheimer’s disease: Data from the Swedish Dementia Registry, SveDem. Alzheimers Dement11, 1470–1479.
56.
KaerstL, KuhlmannA, WedekindD, StoeckK, LangeP, ZerrI (2013) Using cerebrospinal fluid marker profiles in clinical diagnosis of dementia with Lewy bodies, Parkinson’s disease, and Alzheimer’s disease. J Alzheimers Dis38, 63–73.
57.
van HartenAC, KesterMI, VisserP-J, BlankensteinMA, PijnenburgYAL, van der FlierWM, ScheltensP (2011) Tau and p-tau as CSF biomarkers in dementia: A meta-analysis. Clin Chem Lab Med49, 353–66.
58.
VerweyNA, van der FlierWM, BlennowK, ClarkC, SokolowS, De DeynPP, GalaskoD, HampelH, HartmannT, KapakiE, LannfeltL, MehtaPD, ParnettiL, PetzoldA, PirttilaT, SalehL, SkinningsrudA, SwietenJC, VerbeekMM, WiltfangJ, YounkinS, ScheltensP, BlankensteinMA (2009) A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer’s disease. Ann Clin Biochem46, 235–240.
59.
BiscettiL, SalvadoriN, FarottiL, CataldiS, EusebiP, PaciottiS, ParnettiL (2019) The added value of Aβ42/Aβ40 in the CSF signature for routine diagnostics of Alzheimer’s disease. Clin Chim Acta494, 71–73.
60.
DoreyA, Perret-LiaudetA, TholanceY, FourierA, QuadrioI (2015) Cerebrospinal fluid Aβ40 improves the interpretation of Aβ42 concentration for diagnosing Alzheimer’s disease. Front Neurol6, 247.
61.
LewczukP, LelentalN, SpitzerP, MalerJM, KornhuberJ (2014) Amyloid-β 42/40 cerebrospinal fluid concentration ratio in the diagnostics of Alzheimer’s disease: Validation of two novel assays. J Alzheimers Dis43, 183–191.
JohnsonJK, HeadE, KimR, StarrA, CotmanCW (1999) Clinical and pathological evidence for a frontal variant of Alzheimer disease. Arch Neurol56, 1233–1239.
LewczukP, RiedererP, O’BryantSE, VerbeekMM, DuboisB, VisserPJ, JellingerKA, EngelborghsS, RamirezA, ParnettiL, JackCR, TeunissenCE, HampelH, LleóA, JessenF, GlodzikL, de LeonMJ, FaganAM, MolinuevoJL, JansenWJ, WinbladB, ShawLM, AndreassonU, OttoM, MollenhauerB, WiltfangJ, TurnerMR, ZerrI, HandelsR, ThompsonAG, JohanssonG, ErmannN, TrojanowskiJQ, KaracaI, WagnerH, OecklP, van Waalwijk van DoornL, BjerkeM, KapogiannisD, KuiperijHB, FarottiL, LiY, GordonBA, EpelbaumS, VosSJB, KlijnCJM, Van NostrandWE, MinguillonC, SchmitzM, GalloC, Lopez MatoA, ThibautF, ListaS, AlcoleaD, ZetterbergH, BlennowK, KornhuberJ, Members of the WFSBP Task Force Working on this Topic: Peter Riederer, Carla Gallo, Dimitrios Kapogiannis, Andrea Lopez Mato, Florence Thibaut (2018) Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World J Biol Psychiatry19, 244–328.
67.
HerholzK (2014) Guidance for reading FDG PET scans in dementia patients. Q J Nucl Med Mol Imaging58, 332–343.
68.
Ben BouallègueF, Mariano-GoulartD, PayouxP, Alzheimer’s Disease Neuroimaging Initiative (ADNI) the ADNI (2017) Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer’s disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database. Alzheimers Res Ther9, 32.
69.
JansenWJ, OssenkoppeleR, KnolDL, TijmsBM, ScheltensP, VerheyFRJ, VisserPJ, Amyloid Biomarker Study Group, AaltenP, AarslandD, AlcoleaD, AlexanderM, AlmdahlIS, ArnoldSE, BaldeirasI, BarthelH, van BerckelBN, BibeauK, BlennowK, BrooksDJ, van BuchemMA, CamusV, CavedoE, ChenK, ChetelatG, CohenAD, DrzezgaA, EngelborghsS, FaganAM, FladbyT, FleisherAS, van der FlierWM, FordL, FörsterS, ForteaJ, FoskettN, FrederiksenKS, Freund-LeviY, FrisoniGB, FroelichL, GabryelewiczT, GillKD, GkatzimaO, Gómez-TortosaE, GordonMF, GrimmerT, HampelH, HausnerL, HellwigS, HerukkaSK, HildebrandtH, IshiharaL, IvanoiuA, JagustWJ, JohannsenP, KandimallaR, KapakiE, Klimkowicz-MrowiecA, KlunkWE, KöhlerS, KoglinN, KornhuberJ, KrambergerMG, Van LaereK, LandauSM, LeeDY, de LeonM, LisettiV, LleóA, MadsenK, MaierW, MarcussonJ, MattssonN, de MendonçaA, MeulenbroekO, MeyerPT, MintunMA, MokV, MolinuevoJL, MøllergårdHM, MorrisJC, MroczkoB, Van der MusseleS, NaDL, NewbergA, NordbergA, NordlundA, NovakGP, ParaskevasGP, ParnettiL, PereraG, PetersO, PoppJ, PrabhakarS, RabinoviciGD, RamakersIH, RamiL, Resende de OliveiraC, RinneJO, RodrigueKM, Rodríguez-RodríguezE, RoeCM, RotU, RoweCC, RütherE, SabriO, Sanchez-JuanP, SantanaI, SarazinM, SchröderJ, SchütteC, SeoSW, SoeteweyF, SoininenH, SpiruL, StruyfsH, TeunissenCE, TsolakiM, VandenbergheR, VerbeekMM, VillemagneVL, VosSJ, van Waalwijk van DoornLJ, WaldemarG, WallinA, WallinÅK, WiltfangJ, WolkDA, ZbochM, ZetterbergH (2015) Prevalence of cerebral amyloid pathology in persons without dementia: A meta-analysis. JAMA313, 1924–1938.
